23,338,039
Vote Records
27,979
Companies
11,817
Funds
4,051
Managers

Home › Companies › PTC Therapeutics, Inc. › 2025-2026

PTC Therapeutics, Inc. 2025-2026 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and PTC Therapeutics, Inc.’s Form 8-K, filed June 5, 2026 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 6Reported items
  • 349Asset managers, any item
  • 3,025Fund votes
  • June 2, 2026Meeting date

Results at a glance

Meeting of June 2, 2026: 4 items on PTC Therapeutics, Inc.’s Form 8-K, filed June 5, 2026: 4 passed (calculated).

Dissent

No notable dissent.

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Activist investors: Tang Capital (13F, 1.8%, as of September 30, 2026)

Explore PTC Therapeutics, Inc. in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by PTC Therapeutics, Inc.

These tallies are PTC Therapeutics, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 5, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

PTC Therapeutics, Inc. — official shareholder meeting results, meeting held June 2, 2026
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Jessica Chutter 71,945,515---- 737,7803,858,311 99%Passed (calculated)—
Elect Director: Matthew B. Klein, M.D., M.S., F.A.C.S. 71,550,878---- 1,132,4173,858,311 98%Passed (calculated)—
Elect Director: Stephanie S. Okey, M.S. 68,902,707---- 3,780,5883,858,311 95%Passed (calculated)—
Elect Director: Jerome B. Zeldis, M.D., Ph.D. 69,821,943---- 2,861,3523,858,311 96%Passed (calculated)—

Source: PTC Therapeutics, Inc., Form 8-K, filed with the SEC on June 5, 2026 — read the filing on EDGAR.

How asset managers voted at the PTC Therapeutics, Inc. 2025-2026 meeting

349 asset managers disclosed a vote on at least one PTC Therapeutics, Inc. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of PTC Therapeutics, Inc.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

Elect Director: Jerome B. Zeldis, M.D., Ph.D.

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 8 wordings of this item as funds reported it.

96% Majority: yes · of votes cast

FOR 96%
FOR: 69,821,943WITHHELD: 2,861,352
Details: description as filed, official tally, votes by 111 asset managers

Description as filed by funds: Election of Four Class I Directors: Jerome B. Zeldis, M.D., Ph.D.

PTC Therapeutics, Inc.’s own tally for this item (“Elect Director: Jerome B. Zeldis, M.D., Ph.D.”): 69,821,943 for, 2,861,352 withheld, per its Form 8-K filed June 5, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 96% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 111 asset managers below reported 36,152,747 for, 630,941 withheld, 268,996 abstained.

FOR
FOR: 36,152,747ABSTAIN: 268,996WITHHOLD: 630,941
Largest asset managers voting on “Election of Four Class I Directors: Jerome B. Zeldis, M.D., Ph.D.” at PTC Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard10,913,3660 200For
BlackRock8,919,2250 00For
Fidelity3,183,2480 00For
State Street2,643,9650 0146For
JANUS INVESTMENT FUND1,908,5790 00For
Manager Directed Portfolios988,4390 00For
Charles Schwab677,0900 00For
Invesco663,6220 00For
TIAA628,5380 00For
FRANKLIN STRATEGIC SERIES488,1150 00For
Lord Abbett385,3600 00For
Bridge Builder Trust337,4770 00For
T. Rowe Price00 0324,181Withhold
Jackson National299,0940 00For
TRUST FOR PROFESSIONAL MANAGERS66,0330 218,5560Mixed
Hartford262,6120 00For
Dimensional225,7580 00For
Voya220,1680 00For
Equitable132,5090 059,080Mixed
Loomis Sayles176,9050 00For
Federated Hermes148,1710 00For
Columbia Threadneedle147,6230 00For
Russell Investments138,6720 00For
DRIEHAUS MUTUAL FUNDS137,0870 00For
QUANTITATIVE MASTER SERIES LLC127,8430 00For

Showing the 25 largest of 111 asset managers. All 111 are in the interactive database (link above).

Elect Director: Jessica Chutter

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 7 wordings of this item as funds reported it.

99% Majority: yes · of votes cast

FOR 99%
FOR: 71,945,515WITHHELD: 737,780
Details: description as filed, official tally, votes by 111 asset managers

Description as filed by funds: Election of Four Class I Directors: Jessica Chutter

PTC Therapeutics, Inc.’s own tally for this item (“Elect Director: Jessica Chutter”): 71,945,515 for, 737,780 withheld, per its Form 8-K filed June 5, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 99% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 111 asset managers below reported 36,682,283 for, 106,772 withheld, 263,629 abstained.

FOR
FOR: 36,682,283ABSTAIN: 263,629WITHHOLD: 106,772
Largest asset managers voting on “Election of Four Class I Directors: Jessica Chutter” at PTC Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard10,913,3820 40For
BlackRock8,919,2250 00For
Fidelity3,183,2480 00For
State Street2,644,1110 00For
JANUS INVESTMENT FUND1,908,5790 00For
Manager Directed Portfolios988,4390 00For
Charles Schwab677,0900 00For
Invesco663,6220 00For
TIAA628,5380 00For
FRANKLIN STRATEGIC SERIES488,1150 00For
Lord Abbett385,3600 00For
Bridge Builder Trust337,4770 00For
T. Rowe Price324,1810 00For
Jackson National299,0940 00For
TRUST FOR PROFESSIONAL MANAGERS66,0330 218,5560Mixed
Hartford262,6120 00For
Dimensional225,7580 00For
Voya220,1680 00For
Equitable191,5890 00For
Loomis Sayles176,9050 00For
Federated Hermes148,1710 00For
Columbia Threadneedle147,6230 00For
Russell Investments138,6720 00For
DRIEHAUS MUTUAL FUNDS137,0870 00For
QUANTITATIVE MASTER SERIES LLC127,8430 00For

Showing the 25 largest of 111 asset managers. All 111 are in the interactive database (link above).

Elect Director: Matthew B. Klein, M.D., M.S., F.A.C.S.

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 7 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%
FOR: 71,550,878WITHHELD: 1,132,417
Details: description as filed, official tally, votes by 111 asset managers

Description as filed by funds: Election of Four Class I Directors: Matthew B. Klein, M.D., M.S., F.A.C.S.

PTC Therapeutics, Inc.’s own tally for this item (“Elect Director: Matthew B. Klein, M.D., M.S., F.A.C.S.”): 71,550,878 for, 1,132,417 withheld, per its Form 8-K filed June 5, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 98% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 111 asset managers below reported 36,682,135 for, 106,918 withheld, 263,631 abstained.

FOR
FOR: 36,682,135ABSTAIN: 263,631WITHHOLD: 106,918
Largest asset managers voting on “Election of Four Class I Directors: Matthew B. Klein, M.D., M.S., F.A.C.S.” at PTC Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard10,913,3800 60For
BlackRock8,919,2250 00For
Fidelity3,183,2480 00For
State Street2,643,9650 0146For
JANUS INVESTMENT FUND1,908,5790 00For
Manager Directed Portfolios988,4390 00For
Charles Schwab677,0900 00For
Invesco663,6220 00For
TIAA628,5380 00For
FRANKLIN STRATEGIC SERIES488,1150 00For
Lord Abbett385,3600 00For
Bridge Builder Trust337,4770 00For
T. Rowe Price324,1810 00For
Jackson National299,0940 00For
TRUST FOR PROFESSIONAL MANAGERS66,0330 218,5560Mixed
Hartford262,6120 00For
Dimensional225,7580 00For
Voya220,1680 00For
Equitable191,5890 00For
Loomis Sayles176,9050 00For
Federated Hermes148,1710 00For
Columbia Threadneedle147,6230 00For
Russell Investments138,6720 00For
DRIEHAUS MUTUAL FUNDS137,0870 00For
QUANTITATIVE MASTER SERIES LLC127,8430 00For

Showing the 25 largest of 111 asset managers. All 111 are in the interactive database (link above).

Elect Director: Stephanie S. Okey, M.S.

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 7 wordings of this item as funds reported it.

95% Majority: yes · of votes cast

FOR 95%
FOR: 68,902,707WITHHELD: 3,780,588
Details: description as filed, official tally, votes by 111 asset managers

Description as filed by funds: Election of Four Class I Directors: Stephanie S. Okey, M.S.

PTC Therapeutics, Inc.’s own tally for this item (“Elect Director: Stephanie S. Okey, M.S.”): 68,902,707 for, 3,780,588 withheld, per its Form 8-K filed June 5, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 95% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 111 asset managers below reported 36,059,274 for, 724,415 withheld, 268,996 abstained.

FOR
FOR: 36,059,274ABSTAIN: 268,996WITHHOLD: 724,415
Largest asset managers voting on “Election of Four Class I Directors: Stephanie S. Okey, M.S.” at PTC Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard10,900,9940 2012,373For
BlackRock8,919,2250 00For
Fidelity3,183,2480 00For
State Street2,644,1110 00For
JANUS INVESTMENT FUND1,908,5790 00For
Manager Directed Portfolios988,4390 00For
Charles Schwab677,0900 00For
Invesco663,6220 00For
TIAA628,5380 00For
FRANKLIN STRATEGIC SERIES488,1150 00For
Lord Abbett385,3600 00For
Bridge Builder Trust337,4770 00For
T. Rowe Price00 0324,181Withhold
Jackson National299,0940 00For
TRUST FOR PROFESSIONAL MANAGERS66,0330 218,5560Mixed
Hartford262,6120 00For
Dimensional225,7580 00For
Voya220,1680 00For
Equitable132,5090 059,080Mixed
Loomis Sayles176,9050 00For
Federated Hermes148,1710 00For
Columbia Threadneedle147,6230 00For
Russell Investments138,6720 00For
DRIEHAUS MUTUAL FUNDS137,0870 00For
QUANTITATIVE MASTER SERIES LLC127,8430 00For

Showing the 25 largest of 111 asset managers. All 111 are in the interactive database (link above).

Approval on a non-binding, advisory basis, of the Company's named executive officer compensation as described in the…

No official matchFund totals may overlapSECTION 14A SAY-ON-PAY VOTES

Combines 4 wordings of this item as funds reported it.

99% Fund and manager reports combined; may count the same shares twice · no official result

FOR
Details: description as filed, votes by 348 asset managers

Description as filed by funds: Approval on a non-binding, advisory basis, of the Company's named executive officer compensation as described in the proxy statement.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Fund voting reports: 110 asset managers voting on “Approval on a non-binding, advisory basis, of the Company's named executive officer compensation as described ” at PTC Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard10,913,3788 00For
BlackRock8,919,2250 00For
Fidelity3,183,2480 00For
State Street2,644,1110 00For
JANUS INVESTMENT FUND1,908,5790 00For
Manager Directed Portfolios988,4390 00For
Charles Schwab677,0900 00For
Invesco663,6220 00For
TIAA628,5380 00For
FRANKLIN STRATEGIC SERIES488,1150 00For
Lord Abbett385,3600 00For
Bridge Builder Trust337,4770 00For
T. Rowe Price324,1810 00For
Jackson National299,0940 00For
TRUST FOR PROFESSIONAL MANAGERS284,5890 00For
Hartford262,6120 00For
Dimensional225,7580 00For
Voya220,1680 00For
Equitable191,5890 00For
Loomis Sayles176,9050 00For
Federated Hermes148,1710 00For
Columbia Threadneedle147,6230 00For
Russell Investments138,6720 00For
DRIEHAUS MUTUAL FUNDS137,0870 00For
QUANTITATIVE MASTER SERIES LLC127,8430 00For

Fund voting reports, all 110 managers: 36,973,668 for, 6,728 against, 13,167 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 269 asset managers voting on “Approval on a non-binding, advisory basis, of the Company's named executive officer compensation as described ” at PTC Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Janus Henderson11,209,3450 00For
RTW INVESTMENTS, LP7,746,4150 00For
State Street4,110,3400 00For
Wellington3,445,2210 00For
BlackRock2,896,6611,118 00For
GEODE CAPITAL MANAGEMENT, LLC2,217,1940 00For
Hood River Capital Management LLC1,593,5750 00For
Fidelity1,473,7690 00For
FRANKLIN ADVISERS INC1,099,3720 00For
PICTET ASSET MANAGEMENT SA1,080,5890 00For
DE Shaw958,3900 00For
Palo Alto Investors LP918,8460 00For
Charles Schwab735,6650 00For
Invesco718,3470 00For
JUPITER ASSET MANAGEMENT LTD711,4570 00For
DRIEHAUS CAPITAL MANAGEMENT LLC681,9170 00For
Vanguard678,2750 00For
Nuveen650,2330 00For
Northern Trust640,0820 00For
Boston Partners633,4620 00For
Ensign Peak Advisors, Inc606,9990 00For
T. Rowe Price577,3240 00For
PRINCIPAL GLOBAL INVESTORS517,0570 00For
LORD, ABBETT & CO. LLC516,9330 00For
MELLON INVESTMENTS Corp512,8280 00For

Institutional-manager reports, all 269 managers: 53,834,093 for, 991,430 against, 34 abstained, 343 not voted. Showing the 25 largest; every one is in the interactive database (link above).

Ratification of the appointment of Ernst & Young LLP as the company's independent registered public accounting firm for…

No official matchAUDIT-RELATED

99.9% of fund votes cast · no official result

FOR
Details: description as filed, votes by 110 asset managers

Description as filed by funds: RATIFICATION OF THE APPOINTMENT OF ERNST & YOUNG LLP AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2026.

The 110 asset managers below reported 36,931,534 for, 33,510 against, 13,167 abstained. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

FOR: 36,931,534AGAINST: 33,510ABSTAIN: 13,167
Largest asset managers voting on “RATIFICATION OF THE APPOINTMENT OF ERNST & YOUNG LLP AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING” at PTC Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard10,913,3842 00For
BlackRock8,919,2250 00For
Fidelity3,183,2480 00For
State Street2,643,965146 00For
JANUS INVESTMENT FUND1,908,5790 00For
Manager Directed Portfolios988,4390 00For
Charles Schwab677,0900 00For
Invesco663,6220 00For
TIAA628,5380 00For
FRANKLIN STRATEGIC SERIES488,1150 00For
Lord Abbett385,3600 00For
Bridge Builder Trust337,4770 00For
T. Rowe Price324,1810 00For
Jackson National299,0940 00For
TRUST FOR PROFESSIONAL MANAGERS284,5890 00For
Hartford262,6120 00For
Dimensional225,7580 00For
Voya220,1680 00For
Equitable191,5890 00For
Loomis Sayles176,9050 00For
Federated Hermes148,1710 00For
Columbia Threadneedle147,6230 00For
Russell Investments138,6720 00For
DRIEHAUS MUTUAL FUNDS137,0870 00For
QUANTITATIVE MASTER SERIES LLC127,8430 00For

Showing the 25 largest of 110 asset managers. All 110 are in the interactive database (link above).

Largest PTC Therapeutics, Inc. shareholders voting in 2025-2026

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 82,882,024 shares outstanding at the time of that meeting.

Fund voting reports: top PTC Therapeutics, Inc. shareholders by shares voted on “Election of Four Class I Directors: Jerome B. Zeldis, M.D., Ph.D.”, 2025-2026
#Asset manager % of shares outstanding
1Vanguard 13.17%
2BlackRock 10.76%
3Fidelity 3.84%
4State Street 3.19%
5JANUS INVESTMENT FUND 2.30%
6Manager Directed Portfolios 1.19%
7Charles Schwab 0.82%
8Invesco 0.80%
9TIAA 0.76%
10FRANKLIN STRATEGIC SERIES 0.59%
Institutional-manager reports: top PTC Therapeutics, Inc. shareholders by shares voted on “Approval on a non-binding, advisory basis, of the Company's named executive officer…”, 2025-2026
#Asset manager % of shares outstanding
1Janus Henderson 13.52%
2RTW INVESTMENTS, LP 9.35%
3State Street 4.96%
4Wellington 4.16%
5BlackRock 3.50%
6GEODE CAPITAL MANAGEMENT, LLC 2.68%
7Hood River Capital Management LLC 1.92%
8Fidelity 1.78%
9FRANKLIN ADVISERS INC 1.33%
10PICTET ASSET MANAGEMENT SA 1.30%

Reported PTC Therapeutics, Inc. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

PTC Therapeutics, Inc. holdings and ownership disclosed for the 2025-2026 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
BlackRock12,948,717 15.62%Form 13F, quarter ended March 31, 2026
Vanguard Group8,803,203 10.62%Form 13F, quarter ended March 31, 2026
RTW Investments L.P.7,423,970 8.96%Proxy statement (DEF 14A), table as of April 10, 2026
JANUS HENDERSON GROUP PLC7,193,433 8.68%Schedule 13G, filed May 15, 2026
Vanguard Portfolio Management4,871,329 5.88%Schedule 13G, filed April 29, 2026
STATE STREET CORPORATION4,206,126 5.07%Schedule 13G, filed February 9, 2026
Wellington Management3,942,610 4.76%Form 13F, quarter ended March 31, 2026
The Toronto-Dominion Bank3,025,945 3.65%Schedule 13G, filed May 15, 2026
Michael Schmertzler1,749,689 2.11%Proxy statement (DEF 14A), table as of April 10, 2026
D.E. Shaw1,640,381 1.98%Form 13F, quarter ended March 31, 2026

Percentages above are of 82,882,024 shares outstanding, as reported by PTC Therapeutics, Inc. on its Form 10-Q dated March 31, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At PTC Therapeutics, Inc.'s shareholder meeting held June 2, 2026, in the 2025-2026 proxy season, 349 asset managers reported votes on at least one item in their SEC Form N-PX filings, covering 3,025 separate fund positions. Their filings are grouped here into 6 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. PTC Therapeutics, Inc.'s own Form 8-K tally for this meeting is published below, but no row in it could be matched to the most widely held item, so this page states no certified outcome for that item. On that item — Approval on a non-binding, advisory basis, of the Company's named executive officer… — the reporting funds and managers cast 99% of the shares they voted in favour (FOR divided by FOR plus AGAINST plus WITHHELD; abstained and unvoted shares are excluded because neither took a side). Fund and manager reports are combined in it and may count the same shares twice: it adds fund reports to institutional-manager reports, which can cover the same shares. It is not the company's certified result.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from PTC Therapeutics, Inc.’s 10-Q dated March 31, 2026. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

PTC Therapeutics, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).

Cite this page

Proxy Votes Now, “PTC Therapeutics (PTCT) 2026 Annual Meeting: Shareholder Vote Results”, https://proxyvotesnow.com/company/ptc-therapeutics-inc/2026 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.